NRx Pharmaceuticals boosts ATM offering capacity to $20M; previously sold $1.8M

NRX Pharmaceuticals, Inc.

Maximum aggregate offering price increased to $20,000,000 under ATM agreement with H.C. Wainwright & Co.
Approximately $1.8 million in common stock sold prior to the increase.
Prospectus supplement filed on April 17, 2025 to register the additional shares.
Legal opinion on share validity filed as Exhibit 5.1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.